跳至主要内容
临床试验/JPRN-UMIN000032248
JPRN-UMIN000032248尚未招募未知

Mathematical Modeling-based Medication for Minimizing Malignant evolution of Lung Cancer - M5-LC

Sendai Kosei Hospital0 个研究点目标入组 5 人开始时间: 2018年4月20日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
5

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) History of any type of malignancy within the past 5 years (including carcinoma in situ). 2) History of organ transplantation (including hematopoietic stem cell transplantation) 3) Major surgery within one month prior to the first blood sampling in this study. 4) Radiotherapy for brain metastatic or other locally advanced lesions within two weeks prior to the first blood sampling in this study. 5) Concomitant presence of distinct types of lung cancer is confirmed: - Patients with histologically distinct types of lung cancer, including lung squamous cell carcinoma and small cell lung cancer, will be excluded. - Patients with distinct lung adenocarcinomas harboring ALK translocation or ROS1 translocation will be excluded.

研究者

发起方
Sendai Kosei Hospital

相似试验